Chronic immune thrombocytopenic purpura (ITP) is a syndrome of destructive thrombocytopenia due to autoantibodies against platelet-associated antigens. These antigens are most commonly located on the platelet glycoprotein (GP) Ilb/llla complex. In the present studies, w e show that many platelet-associated anti-GPllb/llla autoantibodies from chronic ITP patients depend on conformationally intact GPllb/llla for maximal binding. W e studied anti-GPllb/llla autoantibodies from 19 ITP patients (1 5 platelet-associated, 8 plasma) and alloantibodies from three patients with posttransfusion purpura (anti-PIA1). Antibodies were preincubated with purified intact GPllb/llla, EDTA-dissociated GPllb/llla, GPllla, or GPllb for 2 hours and then residual antibody was measured in an antigen capture assay. The binding results were compared with those obtained HRONIC immune thrombocytopenic purpura (ITP) is C a syndrome of destructive thrombocytopenia caused by autoantibodies against platelet-associated antigens.'.' It is well established that autoantibodies from these patients bind most commonly to the glycoprotein (GP) IIb/lIIa although the location of the antigenic epitopes has only recently been investigated. Studies from our lab~ratory',~ have shown that plasma anti-GPIIb/IIIa autoantibodies from selected patients with chronic ITP react with the carboxytermina1 region (c-terminus) of GPIIla, a region presumed to be cytoplasmic in location. Conversely, autoantibodies eluted from the patients' platelets (platelet-associated autoantibodies), including those from patients with anti-c-terminus plasma autoantibody, react with antigenic epitopes located on other areas of the GPIIb/IIIa complex.' Thus, the same ITP patient may have platelet-associated antibodies that differ in specificity from their plasma antibodies. More recently, Kekomaki et allo have reported that some plasma autoantibodies from ITP patients bind to a 50-Kd cysteine-rich region of GPIIIa.
0 1993 by The American Society of Hematology. 0006-49 71/93/81 05-0028$3.00/0 using antibody preincubated in buffer. Of the 1 5 plateletassociated autoantibodies studied, the intact GPllb/llla complex resulted in greater inhibition of antibody binding than the EDTA-dissociated complex, with a mean inhibition ratio (intact/dissociated) of 7.9 (range, 1.4 to 30.3). Little inhibition was noted using either GPllb or GPllla. Conversely, plasma anti-PIA1 alloantibodies or plasma autoantibodies from ITP patients against the c-terminal region of GPllla were more efficiently inhibited by the dissociated complex or purified GPllla. W e conclude that platelet-associated anti-GPllb/llla autoantibodies in chronic ITP are frequently directed to cation-dependent conformational antigens.
0 1993 by The American Society of Hematology.
MATERIALS AND METHODS

Patients
We studied 19 chronic ITP patients. Most of these patients had severe disease, as shown by the failure of 15 of 19 to attain a complete remission with either corticosteroids or splenectomy. These patients were chosen because they had high levels of anti-GPIIb/IIIa autoantibody that could be evaluated in competitive inhibition studies. In 4 patients, we studied both platelet-associated and plasma antibody; in 11 patients, we studied only platelet-associated antibody; and in 4 other patients, we studied only plasma antibody. All of the plasma antibodies were known to be reactive with the c-terminal region of GPIIIa.' In addition, we evaluated plasma from 3 patients with posttransfusion purpura (PTP) caused by anti-PIAl alloantibodies (2 from our institution and I provided by Dr G. Schmidt, City of Hope Medical Center, Duarte, CA).
Monoclonal Antibodies (MoAbs)
The following MoAbs were used: 2A9 (specific for GPIIb as shown by immunoblotting studies) and 3F5 (specific for the GPIIb/IIIa complex as determined by immunoprecipitation and crossed immunoelectrophoresis studies performed with and without EDTA in the manner described in Woods et al") provided by Dr V. Woods (University of California, San Diego); P41 (specific for CPIIIa as shown by immunoblotting studies) provided by Dr Z. Ruggeri (Scripps Clinic); and HB-43 (specific for human IgG; American Type Culture Collection, Rockville, MD). Radioiodination of HB-43 with '"I was accomplished by the iodogen method. For immunoaffinity purification of glycoproteins, I O mg of antibody (3F5, 2A9, or P41) was coupled to 1 g of cyanogen bromide-activated Sepharose CL4B (Pharmacia, Uppsala, Sweden) according to the manufacturer's instructions.
Preparation of Platelet Lysate
Platelets were washed six times with 0.05 mol/L isotonic citrate buffer, pH 6.5, and solubilized in 1% Triton X-100 in buffer A (20 mmol/L Tris, 150 mmol/L NaCI, 1 mmol/L CaCI2, 1 mmol/L MgCI,, pH 7.4, containing 0.4 mmol/L phenylmethylsulfonyl fluoride [PMSF]) for 30 minutes at 4°C followed by ultracentrifugation at lO0,OOOg for 30 minutes.
Preparation of GPIIb/IIIa Fractions
Platelet lysate, prepared as above (3 to 5 X IO" platelets), was applied to a 3F5-Sepharose CL4B column. After overnight incubation at 4"C, the column was washed extensively
Intact GPllb/IIla complex.
with buffer A containing 1% octylglucopyranoside (OGP). Bound GPIIb/IIIa was eluted with 0.1 mol/L diethylamine in 1% OGPbuffer A, pH IO, and immediately neutralized with 1 mol/L Tris-HCI, pH 6.8, and dialyzed against 0.5% OGP in buffer A, pH 7.4.
Platelet lysate was applied to a 3F5-Sepharose CL4B column as described above and was washed extensively at room temperature with 1% OGP in buffer B (38 mmol/ L Tris, 100 mmol/L glycine, 0.4 mmol/L PMSF, pH 8.7). Dissociated GPIIb and GPIIIa were obtained by incubating the GPIIb/IIla-Sepharose for 2 hours at room temperature with 5 mL of buffer B containing IO mmol/L EDTA. These conditions have been shown to result in complete dissociation of the complex into free GPIIb and GPIIIa.1Z*13 The collected eluate was readsorbed by passage over the same protein-eluted column with the aim of removing any residual intact GPIlb/IIIa complex and was then dialyzed against 0.5% OGPbuffer B containing IO mmol/L EDTA.
Dissociated GPIIb and GPIIIa obtained as described above were used before dialysis for isolation of these glycoproteins. Dissociated GPIIb and GPIIIa from 3 X IO"
platelets were applied to a P41-Sepharose CL4B column (GPIIIaspecific) and incubated for 4 hours at room temperature to allow binding of GPIIIa. The GPIIb-rich eluate was further purified by a second adsorption to a P41-Sepharose CL4B column. To obtain GPIIIa, the P41 column was eluted with 0. I mol/L diethylamine in 1% OGP, IO mmol/L EDTA in buffer B, pH 10, followed by immediate neutralization with 1 mol/L Tris-HCI, pH 6.8. Both the GPIIb-rich and GPIIIa-rich eluates were dialyzed against 0.5% OGP in IO mmol/L EDTA-buffer B.
The protein concentration of each of the above fractions was determined using the Lowry method. Purity was evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE) with Coumassie blue staining and by a direct binding enzyme-linked immunosorbent assay (ELISA). For the latter assay, replicate microtiter wells were coated with 100 pL (5 pg/mL in 0.1 mol/L NaHC03) of each of the glycoprotein fractions for 2 hours at room temperature and then blocked with 2% bovine serum albumin (BSA). Next, 100 pL of either 2A9, 3F5, or P4 I (1 pg/well) was added and incubated for 2 hours at room temperature. Antibody binding was detected using biotinylated antimouse IgG using an avidin-biotin-peroxidase system (Vector Laboratories, Burlingame, CA).
Preparation of Platelet-Associated and Plasma Antibody
Each of the 15 platelet-associated antibodies and the 8 plasma antibodies from chronic ITP patients and the 3 plasma anti-PIA1 alloantibodies showed substantial anti-GPIIb/IIIa activity in the assay system described below. Platelet-associated autoantibodies were eluted from the patients' platelets? Briefly, washed platelets (2 to 10 X lo8) were incubated with 1 mL of 100 mmol/L glycine-HCI, pH 2.5, for 15 minutes at room temperature. After removal of membranes by ultracentrifugation, the supematant fluid was neutralized with I mol/ L Tris, pH 9, and insoluble material was removed by recentrifugation. Plasma was obtained from EDTA-anticoagulated blood. In one patient (ITP-3), plasma antibody was affinity purified using a GPIIb/ IIIa-Sepharose CL4B column' to reduce the high background activity.
Dissociated GPIIb and GPIIIa.
Isolation of GPllb and GPIIIa.
Epitope Specificity of Anti-GPIIb/IIIa Autoantibodies
To evaluate antibody specificity, the plateletassociated or plasma antibody preparations were preincubated for 2 hours at room temperature with equivalent amounts (2 X IO-" mol) of either purified intact GPlIb/IIIa complex, EDTA-dissociated GPIIb/IIIa complex, GPIIb, or GPIIIa to evaluate their ability to compete for the antibody-binding site. Antibody incubated in the appropriate buffer alone served as the control (buffer A for intact GPIIb/IIIa and buffer B for the other glycoprotein fractions). Antibody
Inhibition studies.
activity of all samples was determined using the antigen capture assay described below. In selected experiments, serial dilutions of the glycoprotein fractions were studied. To avoid binding of the preincubated GPIIb/IIIa preparations to the MoAb coated on the microtiter wells (2A9), 5 pg/mL of 2A9 was added to the preincubation solution. Preliminary experiments showed that this addition did not influence results.
Antigen capture assay. Microtiter wells were coated with 100 pL of anti-GPIIb (2A9, 10 pg/mL in 0. I mol/L NaHC03, pH 8.3) for 2 hours at room temperature. After six washes with 0.05% Tween-20 in phosphate-buffered saline (PBS-Tween), the remaining binding sites were blocked with 2% BSA-PBS-Tween for I hour at room temperature followed by six washes with PBS-Tween. Next, 100 pL of platelet lysate ( 108/mL) was added to test wells and 2% BSA was added to control wells followed by 1 hour of incubation. After six washes with PBS-Tween, 100 pL of the platelet-associated or plasma autoantibody preparations (antibody preincubated with the various GP preparations or with buffer only) were added and, after 2 hours of incubation and six washes, well-bound antibody was detected by adding 100 pL of labeled antihuman IgG (HB-43,200,000 cpm/well) for 1 hour. After six final washes, well-bound radioactivity was determined. 4.6 The following conditions in triplicate were included with each assay:
autoantibody preincubated in either buffer A or buffer B alone; autoantibody preincubated with either intact GPIIb/IIIa, dissociated GPIIb/IIIa, GPIIb, or GPIIIa; and BSA controls containing no added platelet lysate assayed in buffer A or buffer B. Autoantibody activity was calculated by subtracting cpm of the BSA control wells from cpm of the platelet lysate (GPIIb/IIIa) wells. The percent inhibition of autoantibody binding due to preincubation with the various glycoprotein fractions was determined using the following formula: percent inhibition = (1 -[mean cpm of wells preincubated with the glycoprotein fraction/mean cpm of wells preincubated with the a p propriate buffer]) X 100. Incubation of platelet eluates from control platelets (IO normal subjects) resulted in essentially unmeasurable binding with well-bound radioactivity less than 100 cpm after subtraction of eluate BSA controls (50 to 125 cpm). Normal plasma resulted in higher well-bound radioactivity (800 to 4,500 cpm), but the results were not significantly different than the plasma BSA controls.6
As a confirmatory assay, selected samples were evaluated for their ability to bind to GP fractions plated directly onto microtiter wells. Purified GP fractions (100 pL at 10 pg/mL of intact GPIIb/IIIa, dissociated GPIIb/IIIa, GPIIb-rich fraction, or GPIIIarich fraction in 0.1 mol/L HC03 buffer) or 2% BSA was added to microtiter wells and incubated for 2 hours at room temperature. After blocking with 2% BSA for 60 minutes and washing six times with PBS-Tween, 100 pL of the platelet-associated or plasma autoantibody preparations was added and, after 2 hours of incubation and six washes, well-bound antibody was detected as described above.
Autoantibody activity was calculated by subtracting cpm of the BSA control wells from cpm of the wells containing purified GP fractions.
Direct assay.
RESULTS
Purification of the GPIIb/IIIa Complex and Its
Components
Analysis of the affinity-purified GPIIb/IIIa fractions by SDS-PAGE under nonreducing conditions is shown in Fig  1. The alkaline eluate from the 3F5 affinity column (intact GPIIb/IIIa complex) and the EDTA eluate from the same column (dissociated GPIIb and GPIIIa) contained two protein bands with molecular weights corresponding to GPIIb and GPIIIa. The unbound material remaining after adsorption to the P4 I column (GPIIb-rich fraction) consisted of a single band consistent with the molecular weight of GPIIb and the alkaline eluate from the same column (GPllla-rich fraction) contained a single protein with the mobility of GPllla. . Purity of these fractions was further studied using a more sensitive method by determining the binding pattern of MoAbs to these fractions (Table I) . Avid binding of 3F5 (GPI I b/I Ila complex-speci fic) to the intact GPI I b/I IIa complex eluted from the 3F5 column by diethylamine was noted, whereas minimal binding to the EDTA-eluted fraction was seen (<570), showing that essentially complete dissociation was achieved. These results are similar to those previously reported by others using crossed The purity of the GPllla-rich fraction was supported by the binding of P-41 (anti-GPllla) and the minimal binding of 2A9 (anti-GPIIb) or 3F5 (complex-specific) to this preparation. The GPlIb fraction showed some contamination with GPIIIa, as evidenced by demonstrable binding of P41 (antiGPllla) when compared with the high-level binding of 2A9 (anti-GPllb).
Based on the competitive inhibition patterns of the GP fractions (Table 2) , the platelet-associated anti-GPIIb/IIla antibodies from these ITP patients bind to epitopes dependent on an intact GPllb/llla complex. Significant inhibition (37% to 98%) ofantibody binding by the intact GPllb/llIa complex was noted in each of the I5 platelet-associated autoantibodies tested, whereas dissociation of the complex with EDTA resulted in a decrease in this inhibition in every case (Table 2) . Attempted reassociation of the complex by adding calcium did not restore the inhibition capacity ofthe intact complex, probably either because of incomplete reassociation or because of inaccurate molecular folding with failure to restore the conformational antigen (data not shown).
As shown by the I/D ratios in Table 2 , intact GPllb/Illa resulted in an average of 7.9 times (range, 1.4 to 30.3) more inhibition than the dissociated GPllb/IIIa complex. These results indicate that these antibodies recognize primarily divalent cationdependent conformational epitopes. The ability of dissociated GPIIb/IIIa and purified GPlIb or GPllla to
Characterization qfEpitope.7 Recognized by PtadetAssociated Airtoantibodies From Clironic ITP Patients
MoAb
Intact GPllb/llla Dissociated GPllb/llla GPllb GPllla
As shown in Table 2 , platelet-associated anti-GPllb/llla tected using an avidin-biotin-peroxidase system. Results are expressed than buffer B (EDTA-containing buffer, column 3).
as optical density. (4) 592 (2) 518 (14) 23.3
Platelet-associated autoantibody was preincubated with either intact GPllb/llla, EDTA-dissociated GPllb/llla, purified GPllb, or purified GPllla. Residual antibody activity after preincubation was compared with autoantibody preincubated in the appropriate buffer alone (buffer A or 8). The data are expressed as radioactivity. The percent inhibition (in parentheses) was calculated as: (1 - [mean cpm of wells preincubated with GPs/mean cpm of wells preincubated with buffer]) X 100.
* I/D ratio equals the percent inhibition by intact GPllb/llla/per percent inhibition by dissociated GPllb/llla.
partially inhibit in some cases (eg, ITP-4 and ITP-16) suggests that some portion of the antigenicity is dependent on either GPIIb or GPIIIa.
To confirm the results of the inhibition studies, selected platelet-associated antibodies (ITP-1, -3, -9, -1 1, -14, and -19) were studied in the direct binding assay in which the glycoprotein fractions are plated directly onto the microtiter wells. As shown in Table 3 , each of the six platelet-associated antibodies tested showed prominent binding to the intact GPIIb/IIIa complex, whereas much less binding to dissociated GPIIb/IIIa, GPIIb, or GPIIIa was noted. Figure 2 shows the complex-specific inhibition pattern of serially diluted GPIIb/IIIa fractions on the binding of one platelet-associated autoantibody (ITP-9).
Characterization of the Epitopes Recognized by Plasma
Anti-GPIIIa c-Terminus Autoantibody and Plasma Anti-PPI Alloantibodies
Plasma antibodies from 8 chronic ITP patients known to have autoantibody to the cytoplasmic portion of GPIIIa' and from 3 patients with alloantibodies to the PIAi alloantigen were also incubated with equimolar amounts of each of the glycoprotein fractions before antibody assay.
As noted in Table 4 , each of the ITP plasma autoantibodies and the three anti-PIAi alloantibodies were inhibited to a greater degree by preincubation with dissociated GPIIb/IIIa than by preincubation with the intact complex, suggesting that these GPIIIa-specific epitopes are more available for antibody binding after divalent cation dissociation of the complex. In addition, binding of these antibodies was also markedly inhibited by the GPIIIa-rich fraction, confirming the location of these epitopes. The lesser inhibition by the GPIIbrich fraction is consistent with the demonstrated contamination of this preparation with GPIIIa as shown by the MoAb binding studies discussed earlier. Two of the antibodies (ITP-6 and PTP-1) were also studied in the direct binding assay (Table 3 ) and showed similar results. Inhibition of one antiPIAi alloantibody (PTP-1) by serial dilutions of each of the fractions is shown in Fig 3. 
DISCUSSION
Many antiplatelet autoantibodies and alloantibodies are directed to epitopes on platelet membrane GPs, particularly the platelet GPIIb/IIIa This complex is a calciumdependent heterodimer expressed on the platelet surface and contains binding sites for fibrinogen, von Willebrand factor, and fibronectin and mediates adhesion between activated Microtiter wells were coated with purified GP fractions. After blocking with 8SA. platelet-associated antibody or plasma was added and, after incubation and washing, well-bound antibody was detected with radiolabeled antihuman IgG. has not been well defined. It is known from the study of wellcharacterized proteins such as cytochrome C l 4 3 l 5 that there are two major types of epitopes: sequential epitopes, which depend on a short sequence of amino acids on a protein, and topographic (configurational) epitopes, which depend on nonsequential amino acids strategically positioned due to molecular folding. We have previously reported that plasma anti-GPIIb/IIIa autoantibodies from several ITP patients (about 10%) react with the putative cytoplasmic (c-terminus) portion of GPIIIa* and demonstrated that this portion of the GPIIIa molecule is only minimally (<5%) expressed on the surface of washed intact platelet^.^ These epitopes are most likely sequential Plasma antibody was preincubated with either intact GPllb/llla, EDTA-dissociated GPllb/llla, purified GPllb, or purified GPllla. Residual antibody activity after preincubation was compared with antibody preincubated in the appropriate buffer alone (buffer A or B). The data are expressed as radioactivity. The percent inhibition (in parentheses) was calculated as: (1 - because some of these antibodies bind to small peptides of 2 1 to 24 amino acids.8 Conversely, platelet-associated autoantibody from the same patients did not bind to this cterminal region but to other as yet unidentified regions on the GPIIb/IIIa molecule, showing that platelet-associated antibodies and plasma antibodies from the same patient may bind to different epitopes. ' In the present studies, we provide evidence that plateletassociated anti-GPIIb/IIIA autoantibodies from many chronic ITP patients bind to complex-dependent configurational epitopes because each of the 15 platelet-associated anti-GPIIb/IIIa autoantibodies that we studied was inhibited by soluble intact GPIIb/IIIa complexes, whereas much less inhibition occurred when EDTA-dissociated GPIIb/IIIa complexes and GPIIb-rich or GPIIIa-rich fractions were used as competitive inhibitors. Conversely, the plasma anti-c-terminus autoantibodies and the anti-PIA' alloantibodies were more efficiently inhibited by EDTA-dissociated GPIIb/IIIa or by purified GPIIIa, suggesting that these GPIIIa-specific antigens are partially hidden and less available for antibody binding in the intact complex.
It is recognized that the ITP patients we studied had particularly severe disease and these results may not reflect the ITP population as a whole. In addition, the plasma autoantibodies from the chronic ITP patients that we studied are present in only a small percentage of those seen in chronic ITP (about 10% to 15%) and it is likely that the specificity of plasma autoantibodies in this disease is much more diverse and that some of these may also react with divalent cationdependent epitopes. Unfortunately, low plasma titers and the lack of binding of many plasma autoantibodies to solubilized GPIIb/IIIa limited the number that we could study using this methodology.
In summary, these results show that platelet-associated autoantibodies against GPIIb/IIIa are often directed to cationdependent conformational epitopes. As more information on the nature of epitopes in this disease is obtained, it may allow a more precise prediction of the therapeutic response and the long-term prognosis.
